Antigen News and Research

RSS

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Researchers in Austria have conducted a study showing that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a significantly more pronounced antibody response to one dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine than previously uninfected individuals.

3 Aug 2021

Study examines efficacy Pfizer-BioNTech vaccine among USAF Academy Cadets

A new study published on the medRxiv* preprint server has estimated the effectiveness of vaccines in preventing COVID-19 as a function of time since vaccination.

3 Aug 2021

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based COVID-19 vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated and safe and is capable of inducing robust antibody responses in vaccine recipients. The study is currently available on the medRxiv* preprint server.

2 Aug 2021

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

A new study published in The New England Journal of Medicine found that in a very small number of cases, people with breakthrough infections might suffer long-lasting COVID-19 symptoms.

2 Aug 2021

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

2 Aug 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Nanocovax is a protein subunit vaccine that contains the full-length spike stabilized by the addition of two prolines

29 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

Amount of testing matters more than the sensitivity of COVID-19 tests

A computational analysis of COVID-19 tests suggests that, in order to minimize the number of infections in a population, the amount of testing matters more than the sensitivity of the tests that are used. Philip Cherian and Gautam Menon of Ashoka University in Sonipat, India, and Sandeep Krishna of the National Centre for Biological Sciences TIFR, Bangalore, India, present their findings in the open-access journal PLOS Computational Biology.

27 Jul 2021

Genomic test may help identify prostate cancer patients at high risk of disease progression

After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.

27 Jul 2021

Scientists identify an antiviral metabolite as a potential serum biomarker for SARS-CoV-2 infection

Scientists from the UK have recently identified an antiviral metabolite 3'-Deoxy-3',4'-didehydro-cytidine as a potential serum biomarker to diagnose active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server while awaiting peer review.

27 Jul 2021

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

A new study evaluates a commercially available IFN‐γ release assay (IGRA) to determine T-cell responses targeted against SARS-CoV-2.

26 Jul 2021

Experts present new research to improve care for head and neck cancers at AHNS 2021

As the international community of experts in head-and-neck cancers gathered virtually last week to share new ideas and treatment strategies at the just-ended American Head & Neck Society (AHNS) 10th International Conference on Head and Neck Cancer, Roswell Park Comprehensive Cancer Center teams are presented new research on both the basic science supporting new treatments as well as opportunities to improve the early and accurate diagnosis of thyroid cancer and other head/neck malignancies.

26 Jul 2021

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

A new study discusses how both different responses to the infection itself and to COVID-19 vaccines are likely the result of genetic differences.

25 Jul 2021

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

23 Jul 2021

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

23 Jul 2021

Researchers use mass spectrometry to study immunogenic SARS-CoV-2 epitopes

A new study has been published on the bioRxiv* preprint server, which has used MS to identify T cell epitopes of SARS-CoV-2 conserved protein, i.e., the membrane glycol protein (MGP) and the non-structure protein-13 (NSP13).

23 Jul 2021

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

A new study characterizes the functional humoral immunity post-COVID-19 mRNA-based vaccination.

22 Jul 2021

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).

22 Jul 2021

Antigen News and Research

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Study examines efficacy Pfizer-BioNTech vaccine among USAF Academy Cadets

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

Amount of testing matters more than the sensitivity of COVID-19 tests

Genomic test may help identify prostate cancer patients at high risk of disease progression

Scientists identify an antiviral metabolite as a potential serum biomarker for SARS-CoV-2 infection

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

Experts present new research to improve care for head and neck cancers at AHNS 2021

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Researchers use mass spectrometry to study immunogenic SARS-CoV-2 epitopes

Efficacy of mRNA vaccine-induced memory B cells against SARS-CoV-2 variants

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics